Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials
call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or
email cancerclinicaltrials@bsd.uchicago.edu.

The study is being conducted to determine whether neoadjuvant endocrine therapy with
fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole
when given before surgery to shrink the cancer and stop it from growing. Anastrozole
inhibits tumor growth by reducing the levels of estrogen and has been approved by the Food
and Drug Administration (FDA) of the United States for use after surgery for postmenopausal
women with estrogen receptor positive breast cancer. It is also considered a standard of
care to give anastrozole for a few months before surgery to shrink the tumor. Fulvestrant
inhibits tumor cell growth by reducing the levels of estrogen receptor in the tumor cell. It
is not approved by the FDA for use in women with early stage breast cancer before or after
surgery, but is approved by the FDA for patients with advanced (Stage 4) estrogen receptor
positive breast cancer that has spread to other parts of the body.